Plain Language Summary {#Sec1}
======================

Immunosuppressive drugs, such as tacrolimus, are crucial in patients after an organ transplant. Without these drugs, the risk of the body rejecting the new organ is increased, which can leave the patient in a life-threatening condition. Tacrolimus was originally available as a twice-daily, immediate-release formulation (IR-T), with rapid absorption of the drug into the body soon after oral administration. A once-daily, extended-release formulation (ER-T) was subsequently developed to reduce the risk of under- and overexposure to tacrolimus by releasing the drug more slowly over a prolonged period of time. There is a lack of data available from clinical practice in the USA regarding the use of ER-T in kidney transplantation. This study compared clinical outcomes and use of healthcare resources over 1 year in kidney transplant patients receiving IR-T or ER-T at a single US transplant center. There was no statistically significant difference in the incidence of kidney rejection or failure in patients receiving ER-T compared with IR-T, although there was a trend toward a lower incidence with ER-T. There was also no statistical difference between the two groups in the use of healthcare resources; however, there was a trend toward fewer days spent hospitalized during the first year, and fewer outpatient clinic visits during the first 3 months after transplantation with ER-T. This study shows that the use of ER-T in US clinical practice can achieve promising outcomes. However, more studies are now needed to investigate whether prescribing ER-T could lead to increased kidney survival and lower healthcare costs compared with IR-T.

Introduction {#Sec2}
============

Extended-release tacrolimus (ER-T) is an oral, once-daily, immunosuppressive agent that was developed to simplify dosing regimens while retaining the safety and efficacy profile of the immediate-release formulation. In 2013, the US regulatory authority granted approval for ER-T on the basis of data from two large randomized controlled trials (RCTs), conducted in 638 and 667 de novo kidney transplant recipients, respectively \[[@CR1], [@CR2]\]. ER-T has, however, been available in the European Union since 2007.

Compared with twice-daily, immediate-release tacrolimus (IR-T), the extended-release formulation has been shown to decrease intrapatient variability in tacrolimus exposure \[[@CR3], [@CR4]\] and offer a smoother blood concentration--time profile \[[@CR3]\]. ER-T may therefore provide a more consistent area under the concentration--time curve over the long term versus the immediate-release formulation. Additionally, once-daily dosing with ER-T has been shown to improve medication adherence compared with IR-T in both kidney and liver transplantation \[[@CR5]--[@CR7]\]. As both high intrapatient variability in tacrolimus exposure and medication nonadherence are associated with reduced graft survival and donor-specific antibody development \[[@CR8]--[@CR13]\], targeting both risk factors with a formulation of tacrolimus that potentially addresses these concerns could be a relevant mechanism to improve long-term outcomes.

In the USA, the overall 5-year kidney graft survival rate ranges from 81% to approximately 90%, depending on race \[[@CR14]\], while the 10-year graft survival rate is between approximately 35% and 50% \[[@CR15]\]. Although 1-year kidney graft survival rates have increased in recent years (currently greater than 90%) \[[@CR14], [@CR15]\], long-term graft survival in the USA remains 25% lower than in other countries with well-developed kidney transplant systems \[[@CR16]\].

Therefore, there is an urgent need to improve long-term outcomes, a goal that could be accomplished by optimizing immunosuppressive regimens. Tacrolimus has a narrow therapeutic index \[[@CR17]\], and so optimizing its exposure is essential, especially as antibody-mediated rejection, now linked to inadequate immunosuppression, is increasingly recognized as a major cause of late graft failure \[[@CR13], [@CR18]\].

The use of ER-T is low in clinical practice in the USA due to higher clinician familiarity with IR-T formulations and limited perceived differences in efficacy and safety compared with IR-T formulations. Notably, the pivotal phase III RCTs for ER-T conducted in de novo kidney transplant recipients excluded patients receiving induction with lymphocyte-depleting agents, an induction strategy employed by many US transplant centers today. Real-world database studies can thus provide further insights into treatment patterns and outcomes for a more heterogeneous patient population versus those enrolled in larger, controlled registrational studies. To our knowledge, no studies have been undertaken to date that examine the clinical outcomes and healthcare resource utilization of kidney transplant patients treated with ER-T under real-world conditions in the modern era of immunosuppression. As such, we utilized data from the Northwestern Medicine Enterprise Data Warehouse with the aim of conducting a retrospective, real-world study of clinical outcomes and healthcare resource utilization in kidney transplant patients receiving ER-T versus IR-T at a single US transplant center.

Methods {#Sec3}
=======

Study Design {#Sec4}
------------

This was a retrospective, single-center, database analysis conducted between February and June 2016. Data for eligible adult patients who had received a kidney transplant during the 4 years preceding the study (January 2012--January 2016) were extracted from the Northwestern Medicine Enterprise Data Warehouse. This database is a single, comprehensive, integrated repository that captures all electronic health records at clinical facilities within the Northwestern Medicine integrated healthcare system (Illinois, USA). Extracted data were de-identified before analysis. This retrospective database analysis study had approval of the Northwestern University Institutional Review Board (IRB\#STU0020221) and adhered to the 1964 Helsinki declaration and its later amendments or comparable ethical standards. As a retrospective study, informed consent of individuals was not required.

Study Population {#Sec5}
----------------

Data were collected for adult patients who had received a kidney transplant at Northwestern Medicine within the study period, who were initiated or switched to routine maintenance immunosuppression with once-daily, ER-T (Astagraf XL^®^, Astellas Pharma US, Inc., Northbrook, IL; also known outside the USA as Advagraf^®^, Graceptor^®^, and Prograf^®^ XL) within 10 days of transplantation, and who continued this regimen for at least 3 months. Per center protocol for tacrolimus initiation, patients received IR-T if therapy was initiated during the initial hospital stay and, subsequently, were switched to ER-T upon hospital discharge. If the first dose of tacrolimus therapy was initiated after hospital discharge, patients were started and maintained on ER-T. Patient cases were matched with control patients who were taking either generic or branded forms of IR-T. Those receiving maintenance therapy with drugs other than tacrolimus (e.g., cyclosporine, belatacept, or sirolimus), or who were participating in a clinical trial during the study period, were excluded.

Endpoints {#Sec6}
---------

Clinical outcomes and healthcare resource utilization were assessed at 30, 90, and 365 days post-transplantation. Clinical outcomes included the incidence of biopsy-confirmed acute rejection (BCAR), graft loss (defined as a return to dialysis, primary graft nonfunction, or dialysis for more than 3 months), the need for retransplantation, and mortality. Estimated glomerular filtration rate (eGFR) by the Modification of Diet in Renal Disease-4 formula, and the proportion of patients experiencing delayed graft function (defined as a requirement for renal replacement therapy within 7 days of transplantation) were also analyzed. Healthcare resource utilization was tracked and included the number of all-cause outpatient clinic visits, number of all-cause readmissions, total number of all-cause hospitalization days, and total number of all-cause emergency room visits to Northwestern University facilities. The number of renal biopsies within 365 days of transplantation was also assessed.

The time to reach a tacrolimus trough level of 6--10 ng/mL (therapeutic target) was evaluated, as well as the number of dose adjustments required to reach this target. Tacrolimus trough levels were also compared between patients treated with the IR-T formulation (using trough levels from at least 30 days post-transplantation), and those who received ER-T (from at least 30 days after initiation or switching from the IR-T to the ER-T formulation).

Data Analysis and Statistical Methods {#Sec7}
-------------------------------------

Patients receiving ER-T were matched 1:3 with those receiving IR-T. Patients were propensity score matched for 15 patient demographic and clinical characteristics present at the time of their first transplant procedure. These characteristics included sex, race/ethnicity, payer type, organ donor type (living versus deceased), induction regimen, steroid use, panel reactive antibody score, kidney donor profile index, transplantation status (retransplant), time on dialysis, comorbid conditions (such as obesity, diabetes, hypertension, or focal segmental glomerulosclerosis), number of human leukocyte antigen mismatches, and number of days post-transplantation prior to tacrolimus administration. Among the possible control patients who met these criteria for a given case, the three with the closest propensity score to that of the case were selected. This process was conducted in a randomly assigned order by case; selection of controls was made without replacement.

Recipient age and the Charlson Comorbidity Index were excluded from the propensity score model and exact-matched instead. Specifically, an exact match was performed on tertiles of age and Charlson Comorbidity Index, and quintiles of propensity score, in order to limit selection bias.

For the analysis of eGFR, values greater than 60 mL/min/1.73 m^2^ were truncated, with values reported only as high as 60 mL/min/1.73 m^2^ given that values above this threshold can be unreliable \[[@CR19]\].

The comparisons between groups were made using generalized estimating equations to account for the match. Comparisons were considered statistically significant at the *p* \< 0.05 level. All analyses were performed using SAS^®^ version 9.4, and R version 3.2.2 using the R Studio interface.

Results {#Sec8}
=======

Patient Demographics and Clinical Characteristics {#Sec9}
-------------------------------------------------

During the observation period, 19 patients were initiated on treatment with ER-T, or were converted to treatment from IR-T to ER-T within 10 days post-transplantation, and continued therapy for a period of at least 3 months. Of these 19 patients, 17 (89.5%) received ER-T as part of their planned discharge immunosuppression regimen, one (5.3%) received ER-T because of loss of insurance, and one (5.3%) received ER-T because of concern over deteriorating renal function (no further details available). The 19 patients were subsequently matched with 55 patients treated with IR-T (Table [1](#Tab1){ref-type="table"}). The exact proportions of patients receiving generic versus branded forms of IR-T were unavailable; however, use of generic preparations increased during the study period.Table 1Patient demographics and clinical characteristicsParameterExtended-release tacrolimus (*N* = 19)Immediate-release tacrolimus (*N* = 55)*p* valueSex0.90  Female7 (36.8)21 (38.2)  Male12 (63.2)34 (61.8)Race/ethnicity0.45  Asian2 (10.5)5 (9.1)  Hispanic6 (31.6)15 (27.3)  Non-Hispanic black1 (5.3)14 (25.5)  Non-Hispanic white10 (52.6)21 (38.2)Insurance0.39  Medicaid1 (5.3)6 (10.9)  Medicare7 (36.8)26 (47.3)  Private11 (57.9)23 (41.8)Education0.39  Attended some college1 (5.3)18 (32.7)  Bachelors/associate degree5 (26.3)11 (20.0)  Grade school2 (10.5)4 (7.3)  High school10 (52.6)19 (34.5)  Postgraduate degree1 (5.3)3 (5.5)Primary language0.42  English15 (78.9)47 (85.5)  Spanish4 (21.1)6 (10.9)  Other0 (0.0)2 (3.6)Obesity0.19  Normal weight5 (26.3)16 (29.1)  Obese6 (31.6)18 (32.7)  Overweight5 (26.3)21 (38.2)  Underweight3 (15.8)0 (0.0)PRA0.68  Highly sensitized \[81+\]2 (10.5)4 (7.3)  Sensitized \[21--80\]3 (15.8)11 (20.0)  Unsensitized \[0--20\]14 (73.7)40 (72.7)Induction regimen0.13  Alemtuzumab11 (57.9)47 (85.5)  Basiliximab7 (36.8)8 (14.5)  Neither1 (5.3)0 (0.0)Steroid use after 3 months post-transplantation0.11  Yes9 (47.4)17 (30.9)  No10 (52.6)37 (67.3)  Unknown0 (0.0)1 (1.8)Prior transplant0.79  No19 (100.0)52 (94.5)  Yes0 (0.0)3 (5.5)Number of HLA-A mismatches0.34  05 (26.3)19 (34.5)  112 (63.2)31 (56.4)  22 (10.5)5 (9.1)Number of HLA-B mismatches0.49  06 (31.6)13 (23.6)  111 (57.9)41 (74.5)  22 (10.5)1 (1.8)Number of HLA-DR mismatches0.41  08 (42.1)20 (36.4)  19 (47.4)29 (52.7)  22 (10.5)6 (10.9)Number of HLA-A, -B, -DR mismatches0.57  01 (5.3)1 (1.8)  11 (5.3)1 (1.8)  20 (0.0)1 (1.8)  33 (15.8)7 (12.7)  42 (10.5)11 (20.0)  57 (36.8)18 (32.7)  65 (26.3)16 (29.1)Diabetes0.94  No15 (78.9)44 (80.0)  Yes4 (21.1)11 (20.0)Hypertension0.30  No10 (52.6)32 (58.2)  Yes9 (47.4)23 (41.8)Polycystic kidney disease0.63  No16 (84.2)48 (87.3)  Yes3 (15.8)7 (12.7)Glomerulonephritis0.62  No18 (94.7)51 (92.7)  Yes1 (5.3)4 (7.3)IgA nephropathy0.27  No18 (94.7)49 (89.1)  Yes1 (5.3)6 (10.9)Focal segmental glomerulosclerosis0.40  No18 (94.7)51 (92.7)  Yes1 (5.3)4 (7.3)Systemic lupus erythematosus0.99  No18 (94.7)52 (94.5)  Yes1 (5.3)3 (5.5)Other diagnosis0.99  No16 (84.2)49 (89.1)  Yes3 (15.8)6 (10.9)*HLA* human leukocyte antigen, *IgA* immunoglobulin A, *PRA* panel reactive antibodyData are*n* (%)

During the study period, four patients (21.1%) switched from ER-T to IR-T. One of these patients showed borderline changes on a protocol biopsy at 3 months, with new onset BK viruria; one had changes suggestive of borderline cellular infiltrates with subtherapeutic tacrolimus levels at 3 months; and one patient was highly sensitized and experienced supratherapeutic tacrolimus levels on the extended-release preparation. The fourth patient switched to IR-T because of cost differences between generic IR-T and the branded ER-T formulation.

As anticipated, there were no significant differences in baseline covariates between the ER-T and IR-T groups after propensity score and exact matching (Table [1](#Tab1){ref-type="table"}). Most patients receiving ER-T were male (63.2%), with a mean ± standard deviation (SD) age of 49.5 ± 16.3 years (range 23.0--74.0 years) at transplantation. Patients taking ER-T had received dialysis for a mean ± SD of 3.1 ± 3.7 years at the time of transplantation, had a mean kidney donor profile index of 38.1 ± 23.3%, and a mean Charlson Comorbidity Index score of 3.7 ± 1.4 points. Most patients received induction therapy with alemtuzumab (57.9%) or basiliximab (36.8%). The median time between transplantation and initiation of ER-T treatment was 1.5 days (interquartile range 1.3--3.0 days), with patients receiving ER-T for a median of 490.0 days (interquartile range 111.0--632.0 days).

Mortality and Graft Loss {#Sec10}
------------------------

No patients (0/19) in the ER-T group experienced a BCAR event compared with 3/55 (5.5%) patients in the IR-T group. As previously noted, one patient on ER-T showed borderline changes on a protocol biopsy at 3 months with new onset BK viruria and one patient had changes suggestive of borderline cellular infiltrates at 3 months with subtherapeutic tacrolimus levels. Neither of these patients met Banff diagnostic criteria for BCAR. Graft failure did not occur in any patients in the ER-T group (0/19) compared with 3/55 (5.5%) patients in the IR-T group. No patients required retransplantation or died during the study, in either cohort.

Renal Function {#Sec11}
--------------

No patients in either treatment group experienced delayed graft function post-transplantation. Mean eGFR ranged between 46.2 and 52.6 mL/min/1.73 m^2^ across time points and treatment groups. The values were similar in both treatment groups at 30, 90, and 365 days post-transplantation (*p* = 0.71, *p* = 0.51, and *p* = 0.47, respectively), the caveat being that data were capped when patients achieved the maximum eGFR of 60 mL/min/1.73 m^2^ (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Median estimated glomerular filtration rate at 30, 90, and 365 days post-transplantation for patients who received extended-release (*N* = 19) or immediate-release tacrolimus (*N* = 55). Whiskers represent range. \*eGFR was capped at 60 mL/min/1.73 m^2^

Tacrolimus Dose and Trough Levels {#Sec12}
---------------------------------

There were no significant differences between the ER-T and IR-T groups with regard to the number of days (mean ± SD) taken to reach the target trough level of 6--10 ng/mL (9.2 ± 8.3 versus 7.8 ± 7.9 days, respectively; *p* = 0.18), or the number of dose adjustments required to reach the target trough level (1.3 ± 1.3 versus 0.9 ± 1.3 adjustments; *p* = 0.13). The number of tacrolimus trough levels drawn was similar in both treatment groups at 30, 90, and 365 days post-transplantation (Table [2](#Tab2){ref-type="table"}). There was also no significant difference in tacrolimus trough levels (mean ± SD) beyond 30 days post-transplant with ER-T compared with IR-T (8.5 ± 1.2 versus 7.7 ± 1.3 ng/mL, respectively; *p* = 0.51) (Table [3](#Tab3){ref-type="table"}). The dose-unadjusted SDs of tacrolimus trough concentrations were also similar in both treatment groups after 30 days post-transplant.Table 2Number of tacrolimus trough concentration measurementsTime point post-transplant (days)Extended-release tacrolimus (*N* = 19)Immediate-release tacrolimus (*N* = 55)*p* valueTacrolimus measurements, mean (SD)3011.8 (1.8)11.9 (2.6)0.589025.6 (3.6)26.1 (7.1)0.4136547.0 (14.5)46.9 (18.1)0.51*SD* standard deviationTable 3Tacrolimus trough levels beyond 30 days post-transplantExtended-release tacrolimus (*N* = 19)Immediate-release tacrolimus (*N* = 55)*p* valueTacrolimus trough levels, ng/mL, mean (SD)8.5 (1.2)7.7 (1.3)0.51*n*1952*SD* standard deviation

Clinic Visits and Hospitalization {#Sec13}
---------------------------------

The mean number of all-cause outpatient clinic visits by 365 days post-transplantation was 4.8 in the ER-T group and 4.4 in the IR-T group (*p* = 0.72). The mean number of all-cause outpatient clinic visits within 30 days was lower with ER-T, but this difference reached only borderline statistical significance (1.0 ± 0.3 versus 1.5 ± 1.2; *p* = 0.05). No statistically significant differences were seen between the two treatment groups regarding the number of outpatient clinic visits within 90 days post-transplantation (*p* = 0.13) and the mean number of readmissions at 30, 90, and 365 days post-transplantation (*p* = 0.38, *p* = 0.41, and *p* = 0.52, respectively) (Table [4](#Tab4){ref-type="table"}). The total number of all-cause hospitalization days within 30 and 90 days post-transplantation was also similar in the ER-T group versus the IR-T group (*p* = 0.42 and *p* = 0.77, respectively) (Table [4](#Tab4){ref-type="table"}). By 365 days post-transplantation, the number of all-cause hospitalization days was numerically greater with IR-T versus ER-T; however, this difference was not statistically significant (3.4 ± 7.3 versus 1.4 ± 2.7 days; *p* = 0.86).Table 4Clinic visits and hospitalization post-transplantationParameterExtended-release tacrolimus (*N* = 19)Immediate-release tacrolimus (*N* = 55)*p* valueNumber of all-cause outpatient clinic visits (days)  Within 301.0 ± 0.3\[0.0--2.0\]1.5 ± 1.2\[0.0--8.0\]0.05  Within 902.0 ± 0.7\[0.0--3.0\]2.5 ± 1.8\[1.0--10.0\]0.13  Within 3654.8 ± 1.3\[2.0--8.0\]4.4 ± 2.1\[1.0--11.0\]0.72Number of all-cause readmissions (days)  Within 300.3 ± 0.6\[0.0--2.0\]0.3 ± 0.5\[0.0--2.0\]0.38  Within 900.5 ± 1.0\[0.0--4.0\]0.6 ± 1.0\[0.0--4.0\]0.41  Within 3650.9 ± 1.2\[0.0--4.0\]1.1 ± 2.1\[0.0--11.0\]0.52Total number of all-cause hospitalizations (days)  Within 300.7 ± 1.6\[0.0--5.0\]0.7 ± 2.3\[0.0--14.4\]0.42  Within 900.7 ± 1.6\[0.0--5.0\]1.8 ± 4.5\[0.0--25.2\]0.77  Within 3651.4 ± 2.7\[0.0--10.0\]3.4 ± 7.3\[0.0--32.2\]0.86Total number of all-cause emergency room visits (days)  Within 300.0 ± 0.0\[0.0--0.0\]0.1 ± 0.3\[0.0--1.0\]  Within 900.0 ± 0.0\[0.0--0.0\]0.2 ± 0.4\[0.0--2.0\]  Within 3650.0 ± 0.0\[0.0--0.0\]0.3 ± 0.9\[0.0--6.0\]Number of renal biopsies within 365 days post-transplantation0.9 ± 0.3\[0.0--1.0\]1.6 ± 0.8\[0.0--4.0\]0.01*SD* standard deviationData are mean ± SD \[range\]

There were no emergency room visits for patients receiving ER-T compared with 0.3 ± 0.9 visits for patients receiving IR-T within 365 days post-transplantation (Table [4](#Tab4){ref-type="table"}). Significantly fewer renal biopsies were performed within 365 days post-transplantation in the ER-T versus the IR-T group (0.9 ± 0.3 versus 1.6 ± 0.8 biopsies; *p* = 0.01) (Table [4](#Tab4){ref-type="table"}).

Discussion {#Sec14}
==========

The aim of this 1-year retrospective analysis exploring clinical outcomes and healthcare resource utilization in matched patients who received ER-T versus IR-T-based maintenance immunosuppression was to further characterize the use of ER-T in a real-world setting. To our knowledge, there is a paucity of data describing outcomes for ER-T under alemtuzumab induction. This is the first study to report the use of ER-T following induction with alemtuzumab in a real-world setting. In addition, while numerous studies have confirmed the safety and efficacy of converting stable adult kidney transplant recipients from IR-T to ER-T \[[@CR20]--[@CR23]\], none of these studies has included patients converted within 10 days after transplantation \[[@CR24]\].

This is the first study reporting outcomes using a novel approach of early conversion from IR-T to ER-T for de novo kidney transplant recipients. Overall, no patients receiving the extended-release formulation experienced BCAR or graft failure, required retransplantation, or died. Renal function was also similar over 1 year of follow-up in both groups.

In this study, most patients received induction therapy with alemtuzumab (57.9%) or basiliximab (36.8%). The regimen was associated with good clinical efficacy, which is in line with low rates of BCAR reported in patients treated with alemtuzumab induction therapy followed by IR-T-based maintenance immunosuppression \[[@CR25]\].

Although 1-year graft and patient survival rates were high with both tacrolimus formulations, no patients receiving ER-T experienced graft failure compared with 5.5% of patients receiving IR-T. Similar 1-year graft and patient survival rates with ER-T and IR-T have been reported previously. For example, in a phase III study of de novo kidney transplant patients, 1-year graft survival rates were 91.5% and 92.8%, with patient survival rates of 96.9% and 97.5% for ER-T and IR-T, respectively \[[@CR2]\]. Another phase III study showed that 1-year graft survival rates were 96.7% and 92.9%, while patient survival rates were 98.6% and 95.7% for ER-T and IR-T, respectively \[[@CR26]\].

In line with the high graft survival rate, the proportion of patients experiencing a BCAR event was low in both treatment groups and consistent with previous publications. For example, results from a phase II study extension showed a high (93.3%) BCAR-free survival rate in de novo kidney transplant patients receiving ER-T at 1 year \[[@CR27]\], which remained greater than 90% at 4 years post-transplantation \[[@CR23]\]. Furthermore, our study supports the similar rate of BCAR between the extended- and immediate-release formulations, as reported by Silva et al. (10.3% versus 7.5%, respectively) \[[@CR26]\]. Indeed, it is encouraging that no patients receiving ER-T in our study experienced BCAR, and outcomes appear to be similar in a real-world setting under alemtuzumab induction and an early conversion strategy from IR-T to ER-T.

Importantly, ER-T and IR-T both supported long-term renal function, as evidenced by comparable eGFR levels between formulations over 1 year of follow-up. These observations agree with Silva et al. who reported a comparable mean eGFR with ER-T and IR-T at 1-year post-transplantation (58.6 mL/min/1.73 m^2^ versus 59.7 mL/min/1.73 m^2^, respectively) \[[@CR26]\]. Our findings are also consistent with the 1-year results of a long-term follow-up study by Van Hooff et al., in which mean serum creatinine and creatinine clearance rates remained stable over 4 years in de novo kidney transplant patients receiving ER-T \[[@CR23]\]. Likewise, good long-term renal function has been reported in kidney transplant recipients converted from IR-T to ER-T. For example, in the R-EVOLUTION study---a 3-year follow-up of 1798 patients who were receiving ER-T from the EVOLUTION trial \[[@CR22], [@CR28]\]---the mean eGFR by the Modification of Diet in Renal Disease-4 remained stable over 3 years after conversion from IR-T (56.7 mL/min/1.73 m^2^ versus 58.1 mL/min/1.73 m^2^ at baseline and year 3, respectively) \[[@CR28]\].

In this study, the time taken to achieve target tacrolimus trough levels was not significantly different between ER-T and IR-T (9.2 versus 7.8 days). Both the number of dose adjustments required to attain target levels and the tacrolimus trough levels on or after 30 days of treatment were also similar between both formulations. Furthermore, these data are consistent with a study of de novo kidney transplant patients in which systemic tacrolimus exposure was similar for both formulations at steady state (following dose adjustment), as evidenced by a comparable area under the concentration--time curve at day 14 and at week 6 \[[@CR27]\]. These data suggest that initiating ER-T in a real-world setting is no more complex than it is with IR-T, and that early conversion from IR-T to ER-T post-transplant yields similar outcomes to that of traditional, continuous treatment with IR-T. Importantly, ER-T provides patients with the option of once-daily dosing of tacrolimus.

Given the reported positive clinical outcomes with ER-T-based immunosuppression, several studies have assessed the economic impact of treating kidney transplant patients with this formulation versus IR-T \[[@CR29]--[@CR31]\]. Such studies have predicted that ER-T would be associated with a range of cost savings due to improved rejection and graft survival rates \[[@CR29]--[@CR31]\]. For example, using cost data from Medicare and the US Renal Data System, Abecassis et al. showed that ER-T was associated with a 5-year cost saving of US\$9411 \[[@CR31]\]. This was driven largely by a reduction in the costs associated with graft loss and dialysis compared with IR-T \[[@CR31]\]. While our study did not directly assess cost savings, we did not find statistically significant differences between treatment groups for the number of outpatient clinic visits, readmissions, hospitalization days, and emergency room visits. However, nonsignificant differences in outpatient clinic visits during the first 90 days, and total hospitalization days during the first 365 days, may have reached statistical significance with a larger number of patients.

A number of limitations in the design of this study should be noted. As this was a retrospective study, a number of study biases are likely to be inherent. First, the number of patients who were available for this study based on the inclusion criteria was small. The study was also undertaken shortly after the introduction of ER-T into the US market when a paucity of real-world data were available characterizing the use of ER-T. The small sample size may have affected the power to detect differences between the two treatment groups. In addition, the center-specific practice of capping the measured eGFR values at 60 mL/min/1.73 m^2^ may have limited the ability to fully assess differences in renal function over time between the two groups. As this study explored the impact of ER-T versus IR-T on clinical and healthcare resource utilization parameters over 1 year only, longer-term differences between the formulations could not be detected. This is noteworthy in that nonadherence to treatment, which has a substantial impact on antibody-mediated rejection, graft survival, and costs \[[@CR11], [@CR13], [@CR32], [@CR33]\], is known to increase over time \[[@CR34]\].

There are several strengths of this study that should be noted. For instance, propensity score matching against a number of characteristics helped control for bias in patient selection between treatment groups. Furthermore, we used a large patient database, which provided real-world data outside of the controlled environment of an RCT. As such, we anticipate that our findings may be more generalizable to other transplant populations receiving ER-T or IR-T in routine clinical settings than data generated from RCTs.

Conclusion {#Sec15}
==========

While ER-T has been available in Europe for almost a decade, to our knowledge this is the first study examining clinical outcomes and healthcare resource utilization of kidney transplant patients treated with the extended-release formulation under US real-world practice conditions. Exploring a real-world data set also enabled us to characterize a unique treatment approach: early conversion from IR-T to ER-T under alemtuzumab induction in de novo kidney transplant recipients. As such, this study affirms that ER-T can be reliably employed in this practice setting, while achieving promising outcomes on a par with those seen in several large European trials. Healthcare resource utilization was generally similar between treatments; however, there were fewer outpatient visits with ER-T at borderline statistical significance (*p* = 0.05). Further investigation in larger real-world studies is warranted to fully characterize the real-world clinical, economic, and resource utilization outcomes with the extended- versus immediate-release formulation employing the use of novel treatment approaches not captured in controlled clinical trials.
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